Showing results (351-360 of 542) with videos related to
Sort By:
Pageof 55
Cell Reports|September 8, 2015
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXRLinara Gabitova, Diana Restifo, Andrey Gorin, et al.Journal of Lipid Research|December 8, 2009
Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infectionRonald W Clark, David Cunningham, Yang Cong, et al.BJC Reports|November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour boardJustin Mencel, Neha Rayarel, Paula Proszek, et al.International Journal of Cancer|June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsFrancesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.British Journal of Cancer|September 22, 2017
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancerFrancesco Sclafani, Gina Brown, David Cunningham, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.Pageof 55